CMS explained that: DSHPs and DSIPs have grown from approximately $886 million in 2019 to nearly $2.7 billion in eligible expenditures in 2025, representing increasing costs to the federal government without a sustainable state contribution. CMSs policy announcement follows another policy change in early March, when CMS signaled it would evaluate state requests for federal Medicaid support for housing and nutrition services and supports on a case-by-case basis rolling back broader flexibilities previously offered to state Medicaid programs to address health-related social needs
What they found: Oral AOD-9604 reduced body fat by 18 to 22 % vs placebo, comparable to injection administration No changes in total body weight (because lean mass rose slightly) Decrease in plasma triglycerides by 30 % Decrease in resting free fatty acids (paradoxically, mobilization of fat from depots into oxidation) No GI side effects Why it matters: It suggested that AOD-9604 could work orally , a rare property for a peptide
Grce son principe actif, la silymarine, l'extrait de chardon-Marie peut exercer ses proprits antioxydantes [2]
This leads to skin laxity, fine lines, and loss of definition in areas like the jawline, neck, and brows
